FY25 Revenue: INR31,724 crores. FY25 EBITDA: INR6,605 crores, margin of 20.8%. Q4 FY25 Revenue: INR8,382 crores. Q4 FY25 EBITDA: INR1,792 crores, margin of 21.4%. Q4 Revenue Growth: 11% year on year, ...
Aurobindo Pharma shares are down nearly 11 percent since the beginning of the year. Shares of Aurobindo Pharma Ltd fell 2.5 percent to Rs 1,161 in morning trade on May 28 after the company reported an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results